Pernix Therapeutics (PTX) Shares Spike - Acquires Great Southern Labs and Looking For More

Article Stock Quotes (1) Comments (0)

Shares of Pernix Therapeutics (NYSE: PTX) are up trading higher this morning, maybe with help from Canaccord Genuity comments. The stock has been on a little bit of a rally, gaining over 13% in the past five trading sessions.

Canaccord analyst, Randall Stanicky, reiterated his 'Buy' rating this morning with a $14 price target.

Stanicky sees PTX staying active in with tuck-in acquisitions, citing the recent announcement PTX bought Great Southern Labs for $4.9 million. PTX has a diverse revenue stream and $39 million in the bank, so expect the company to remain active on the business development front.

The stock is currently trading at $7.77...the 52-wk trading range is $5.90-11.50. However, volume is relatively light.

To see more ratings on PTX, Click Here

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Bausch & Lomb near deal to sell to Valeant Pharmaceuticals (VRX) - WSJ
• Imperial Capital Boosts Price Target on Dick's (DKS); 'Best-of-Breed'
• Janney Capital Boosts PT on Gap (GPS) Post Q1

Create E-mail Alert Related Categories

Analyst Comments, Mergers and Acquisitions

Related Entities

Canaccord Genuity

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?